A patient who accidentally received Lu-177 DOTATATE peptide receptor therapy just 48 hours after octreotide showed no reduction in tumor uptake, suggesting the washout period may be unnecessary.
48 hours vs 4 weeksPRRT given 48 hours after octreotide showed identical tumor uptake compared to the standard 4-week washout
What the researchers found
A 68-year-old man with metastatic small bowel neuroendocrine tumor received his fourth cycle of 177Lu-DOTATATE PRRT only 48 hours after his last dose of octreotide LAR, compared to the approximately 4-week interval used for his first 3 cycles. Tumoral uptake was not reduced at all compared to previous cycles, suggesting octreotide LAR does not meaningfully compete with 177Lu-DOTATATE for somatostatin receptor binding in this timeframe.
Why it matters
If somatostatin analogs like octreotide don't need to be stopped before PRRT, patients could continue receiving the symptom-controlling benefits of octreotide right up to therapy. The current washout period can cause symptom flare-ups and scheduling difficulties, so eliminating it would improve patient quality of life and treatment logistics.
How the study worked
This is a single-patient case report comparing tumoral uptake of 177Lu-DOTATATE across 4 PRRT cycles in the same patient. The first 3 cycles followed standard protocol (~4 weeks after octreotide LAR), while the fourth was administered 48 hours after octreotide due to a scheduling error. Uptake was assessed using standard nuclear medicine imaging.
What this study cannot tell us
This is a single case report — the lowest level of clinical evidence. The finding in one patient cannot be generalized without larger studies. There was no formal pharmacokinetic analysis, and uptake assessment was qualitative rather than rigorously quantitative.
How to read the evidence
This is a single case report, the lowest tier of clinical evidence. While the observation is notable and consistent with emerging data, it cannot establish a recommendation on its own.
When this study was published
Published in 2023, this case contributes to an active and ongoing debate about optimizing PRRT protocols for neuroendocrine tumors.
The bigger picture
PRRT with 177Lu-DOTATATE (Lutathera) is a major advance in neuroendocrine tumor treatment. The question of whether octreotide must be stopped beforehand has been debated, with accumulating case evidence suggesting it may not be necessary. This case adds to that body of evidence, though randomized trials are still needed.
Questions still open
- Would a randomized trial confirm that octreotide washout is unnecessary before PRRT across different tumor types and burden levels?
- Does continuing octreotide through PRRT affect long-term treatment outcomes like progression-free survival?
- Are there specific patient or tumor characteristics where the washout period might still matter?
Common questions
What is peptide receptor radionuclide therapy (PRRT)?
Why would octreotide normally be stopped before PRRT?
Read the original research
Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide.
Clinical nuclear medicine, 48(12), 1086-1088
Citation
Low, Han Chung; Tay, Young Soon; Ong, Simon Yew Kuang; Tham, Wei Ying; Yan, Sean Xuexian. (2023). Peptide Receptor Radionuclide Therapy Performed Shortly After Administration of Long-Acting Octreotide.. Clinical nuclear medicine, 48(12), 1086-1088. https://doi.org/10.1097/RLU.0000000000004906